Surface Logix raises $20M to progress pipeline

16 March 2009

Boston, USA-based Surface Logix has raised over $20.0 million in a combined equity and debt financing. The company received around $15.0  million through equity contributions by existing investors, including  ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital,  Saudi Venture Development Company, Unilever Technology Ventures and  Venrock Associates. In addition, MPM Capital participated as a new  investor. On top of the equity round, $5.0 million was raised through a  venture loan from Silicon Valley Bank.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight